1. Home
  2. KZR vs CING Comparison

KZR vs CING Comparison

Compare KZR & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kezar Life Sciences Inc.

KZR

Kezar Life Sciences Inc.

N/A

Current Price

$6.03

Market Cap

44.5M

Sector

Health Care

ML Signal

N/A

CING

Cingulate Inc.

HOLD

Current Price

$6.45

Market Cap

40.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KZR
CING
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.5M
40.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
KZR
CING
Price
$6.03
$6.45
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$6.00
$31.33
AVG Volume (30 Days)
38.0K
332.3K
Earning Date
03-24-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.53
$3.20
52 Week High
$6.62
$6.74

Technical Indicators

Market Signals
Indicator
KZR
CING
Relative Strength Index (RSI) 37.97 70.12
Support Level $6.05 $5.47
Resistance Level $6.24 $6.67
Average True Range (ATR) 0.12 0.68
MACD -0.02 0.06
Stochastic Oscillator 0.04 61.11

Price Performance

Historical Comparison
KZR
CING

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: